) | |
| Clinical data | |
|---|---|
| AHFS/Drugs.com | International Drug Names |
| Routes of administration | oral |
| ATC code | |
| Legal status | |
| Legal status |
|
| Identifiers | |
IUPAC name
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| CompTox Dashboard (EPA) | |
| ECHA InfoCard | 100.035.373  |
| Chemical and physical data | |
| Formula | C14H22ClNO |
| Molar mass | 255.79 g·mol−1 |
| 3D model (JSmol) | |
| Chirality | Racemic mixture |
SMILES
| |
| |
| (verify) | |
Clobutinol is a cough suppressant distributed by Boehringer Ingelheim, Novartis's Hexal (Sandoz), Stada and possibly other companies.
Side effects and withdrawal
Studies in 2004 had indicated that clobutinol has the potential to prolong the QT interval.[1] Clobutinol was in 2007 determined to cause cardiac arrhythmia in some patients.[2]
Boehringer Ingelheim products containing clobutinol were voluntarily withdrawn from sale in Germany, and the rest of the world, on August 31, 2007.[3]
The approval for Germany and the EU was revoked in 2008.[4]
See also
References
- ^ Bellocq C, Wilders R, Schott JJ, Louérat-Oriou B, Boisseau P, Le Marec H, et al. (November 2004). "A common antitussive drug, clobutinol, precipitates the long QT syndrome 2". Molecular Pharmacology. 66 (5): 1093–102. doi:10.1124/mol.104.001065. PMID 15280442.
- ^ "Clobutinol-haltige Arzneimittel: BfArM ordnet Widerruf der Zulassung an". BfArM (German Federal Institute for Drugs and Medical Devices). 2007-08-31. Archived from the original on 2012-04-01.
Clobutinol: BfArM orders cancellation of approval
- ^ "Boehringer Ingelheim voluntarily withdraws its clobutinol containing medications". Boehringer Ingelheim. 2007-08-31. Archived from the original on 2012-01-27.
- ^ "Cancellation of approval" (PDF). BfArM (German Federal Institute for Drugs and Medical Devices). 2008-06-06. Archived from the original (pdf) on 2012-04-01.
Die Zulassungen für die o.g. Arzneimittel werden mit sofortiger Wirkung widerrufen.